NCT06215677View on ClinicalTrials.gov

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

NARecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

May 10, 2025

Study Completion Date

February 10, 2030

Conditions
Colon CancerMismatch Repair DeficiencyImmunotherapy
Interventions
DRUG

Camrelizumab

Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.

Trial Locations (2)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER